HC Wainwright Reiterates “Buy” Rating for Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 140.38% from the stock’s previous close.

Separately, Stifel Nicolaus cut their price target on Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, March 14th.

Nyxoah Trading Up 3.0 %

Shares of NYXH opened at $6.24 on Tuesday. The company has a market capitalization of $212.53 million, a P/E ratio of -3.34 and a beta of 1.55. Nyxoah has a 1-year low of $5.55 and a 1-year high of $12.21. The firm’s 50 day simple moving average is $9.50 and its 200 day simple moving average is $9.22. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The firm had revenue of $1.35 million for the quarter, compared to analysts’ expectations of $2.02 million. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. Sell-side analysts forecast that Nyxoah will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP purchased a new position in shares of Nyxoah in the fourth quarter worth about $23,394,000. Renaissance Technologies LLC acquired a new stake in Nyxoah in the fourth quarter valued at approximately $187,000. Ameriprise Financial Inc. acquired a new stake in Nyxoah in the fourth quarter valued at approximately $135,000. LPL Financial LLC acquired a new stake in shares of Nyxoah in the fourth quarter worth approximately $102,000. Finally, Kovack Advisors Inc. boosted its stake in shares of Nyxoah by 100.0% in the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock worth $160,000 after acquiring an additional 10,000 shares during the last quarter.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.